← Back to Search

Practice E for Papillomavirus Vaccines

N/A
Waitlist Available
Led By Robert M Jacobson, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 11 months (m), 12 m, 13 m, 14 m, 15 m, 16 m, 17 m, 18 m, 19 m, 20 m, 21 m, 22 m, 23 m, 24 m, 25 m, 26 m, 27 m, 28 m, 29 m, 30 m, 31 m, 32 m, 33 m, 34 m, 35 m, 36 m, 37 m, 38 m, 39 m, 40 m, 41 m, 42 m, 43 m, 44 m, 45 m, 46 m, and 47 m
Awards & highlights

Study Summary

This trial will test different ways to get more people to vaccinate against HPV, which causes 30,000 cancers in the US each year.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~11 months (m), 12 m, 13 m, 14 m, 15 m, 16 m, 17 m, 18 m, 19 m, 20 m, 21 m, 22 m, 23 m, 24 m, 25 m, 26 m, 27 m, 28 m, 29 m, 30 m, 31 m, 32 m, 33 m, 34 m, 35 m, 36 m, 37 m, 38 m, 39 m, 40 m, 41 m, 42 m, 43 m, 44 m, 45 m, 46 m, and 47 m
This trial's timeline: 3 weeks for screening, Varies for treatment, and 11 months (m), 12 m, 13 m, 14 m, 15 m, 16 m, 17 m, 18 m, 19 m, 20 m, 21 m, 22 m, 23 m, 24 m, 25 m, 26 m, 27 m, 28 m, 29 m, 30 m, 31 m, 32 m, 33 m, 34 m, 35 m, 36 m, 37 m, 38 m, 39 m, 40 m, 41 m, 42 m, 43 m, 44 m, 45 m, 46 m, and 47 m for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rates of HPV-vaccine receipt
Secondary outcome measures
Rates of HPV vaccine-completion
Rates of HPV vaccine-initiation
Other outcome measures
Rates of HPV-vaccine receipt at 11 years of age
Rates of HPV-vaccine receipt at 12 years of age
Rates of HPV-vaccine receipt in females
+11 more

Trial Design

6Treatment groups
Experimental Treatment
Group I: Practice FExperimental Treatment3 Interventions
Practice F will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice F will be assigned to receive the current care intervention. In the second step, Practice F will be assigned to receive the audit-and-feedback intervention. In the third step, Practice F will receive the combined reminder-recall and audit-and-feedback intervention. In the fourth step, Practice F will receive the combined reminder-recall and audit-and-feedback intervention.
Group II: Practice EExperimental Treatment3 Interventions
Practice E will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice E will be assigned to receive the current care intervention. In the second step, Practice E will be assigned to receive the reminder-recall intervention. In the third step, Practice E will receive the reminder-recall intervention. In the fourth step, Practice E will receive the combined reminder-recall and audit-and-feedback intervention.
Group III: Practice DExperimental Treatment3 Interventions
Practice D will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice D will be assigned to receive the current care intervention. In the second step, Practice D will be assigned to receive the current care intervention. In the third step, Practice D will receive the audit-and-feedback intervention. In the fourth step, Practice D will receive the combined reminder-recall and audit-and-feedback intervention.
Group IV: Practice CExperimental Treatment3 Interventions
Practice C will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice C will be assigned to receive the current care intervention. In the second step, Practice C will be assigned to receive the audit-and-feedback intervention. In the third step, Practice C will receive the audit-and-feedback intervention. In the fourth step, Practice C will receive the combined reminder-recall and audit-and-feedback intervention.
Group V: Practice BExperimental Treatment3 Interventions
Practice B will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice B will be assigned to receive the current care intervention. In the second step, Practice B will be assigned to receive the reminder-recall intervention. In the third step, Practice B will receive the combined reminder-recall and audit-and-feedback intervention. In the fourth step, Practice A will receive the combined reminder-recall and audit-and-feedback intervention.
Group VI: Practice AExperimental Treatment3 Interventions
Practice A will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice A will be assigned to receive the current care intervention. in the second step, Practice A will be assigned to receive the current care intervention. In the third step, Practice A will receive the reminder-recall intervention. In the fourth step, Practice A will receive the combined reminder-recall and audit-and-feedback intervention.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Audit-and-feedback
2022
N/A
~9280
Combined reminder-recall and audit-and-feedback
2018
N/A
~9250
Current care
2018
N/A
~9710
Reminder-recall
2018
N/A
~9250

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,175 Previous Clinical Trials
3,748,919 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,603 Previous Clinical Trials
40,904,033 Total Patients Enrolled
2 Trials studying Papillomavirus Vaccines
5,222 Patients Enrolled for Papillomavirus Vaccines
Robert M Jacobson, MDPrincipal InvestigatorMayo Clinic

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are taking part in this clinical experiment?

"Indeed, the information presented on clinicaltrials.gov affirms that this trial is actively searching for participants; it was initially posted in April of 2018 and has since been updated at the end of July 2022. The research group aims to recruit 10,000 individuals from a single site."

Answered by AI

Does this medical research include participants who are in their mid-fifties or older?

"As stated in the study's inclusion critiera, only participants between the ages of 11 and 12 may be enrolled."

Answered by AI

Is there still availability for participants in this trial?

"According to current information provided by clinicaltrials.gov, this medical research is actively recruiting volunteers. The trial was initiated on April 1st 2018 and has undergone its most recent update on July 28th 2022."

Answered by AI

What qualities make individuals the ideal candidates for this clinical experiment?

"This medical study will recruit 10000 children aged 11-12 who have already received papillomavirus vaccines. These participants need to meet additional criteria, such as having been administered at least one dose of the HPV vaccine over a 12 month period and being registered in one of six primary care practices. It is also essential that they are between eleven and twelve years old when the trial commences."

Answered by AI
~1336 spots leftby Mar 2025